UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prévot 1938

Anaerobe, 2016-08, Vol.40, p.95-99

2016

Volltextzugriff (PDF)

Lactobacillus Species: Taxonomic Complexity and Controversial Susceptibilities

Clinical infectious diseases, 2015-05, Vol.60 (suppl_2), p.S98-S107

2015

Volltextzugriff (PDF)

Bacteriology of Moderate-to-Severe Diabetic Foot Infections and In Vitro Activity of Antimicrobial Agents

Journal of Clinical Microbiology, 2007-09, Vol.45 (9), p.2819-2828

2007

Volltextzugriff (PDF)

Description of two novel members of the family Erysipelotrichaceae: Ileibacterium valens gen. nov., sp. nov. and Dubosiella newyorkensis, gen. nov., sp. nov., from the murine intestine, and emendation to the description of Faecalibacterium rodentium

International journal of systematic and evolutionary microbiology, 2017-05, Vol.67 (5), p.1247-1254

2017

Volltextzugriff (PDF)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin

Clinical infectious diseases, 2012-08, Vol.55 (suppl 2), p.S104-S109

2012

Volltextzugriff (PDF)

Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection

Antimicrobial Agents and Chemotherapy, 2011-11, Vol.55 (11), p.5194-5199

2011

Volltextzugriff (PDF)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates

Antimicrobial Agents and Chemotherapy, 2013-10, Vol.57 (10), p.4872-4876

2013

Volltextzugriff (PDF)

Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II

Clinical infectious diseases, 2020-08, Vol.71 (4), p.1102-1105

2020

Volltextzugriff (PDF)

Antimicrobial Activities of Fidaxomicin

Clinical infectious diseases, 2012-08, Vol.55 (suppl_2), p.S143-S148

2012

Volltextzugriff (PDF)

In Vitro Activity of Tedizolid Compared to Linezolid and Five Other Antimicrobial Agents against 332 Anaerobic Isolates, Including Bacteroides fragilis Group, Prevotella , Porphyromonas , and Veillonella Species

Antimicrobial agents and chemotherapy, 2020-08, Vol.64 (9)

2020

Volltextzugriff (PDF)

Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes

Clinical infectious diseases, 2021-11, Vol.73 (9), p.e2616-e2624

2021

Volltextzugriff (PDF)

Comparative susceptibility of Gemella morbillorum to 13 antimicrobial agents

Anaerobe, 2022-06, Vol.75, p.102573-102573, Article 102573

2022

Volltextzugriff (PDF)

Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities

Journal of antimicrobial chemotherapy, 2020-11, Vol.75 (11), p.3120-3125

2020

Volltextzugriff (PDF)

In Vitro Activity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria

Antimicrobial Agents and Chemotherapy, 2013-06, Vol.57 (6), p.2620-2630

2013

Volltextzugriff (PDF)

Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains

Antimicrobial agents and chemotherapy, 2018-02, Vol.62 (2)

2018

Volltextzugriff (PDF)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence

Antimicrobial Agents and Chemotherapy, 2014-02, Vol.58 (2), p.1187-1191

2014

Volltextzugriff (PDF)

Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

Antimicrobial Agents and Chemotherapy, 2012-05, Vol.56 (5), p.2493-2503

2012

Volltextzugriff (PDF)

In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species

Anaerobe, 2018-08, Vol.52, p.122-124

2018

Volltextzugriff (PDF)

Clostridium difficile Infection Among US Emergency Department Patients With Diarrhea and No Vomiting

Annals of emergency medicine, 2017-07, Vol.70 (1), p.19-27.e4

2017

Volltextzugriff (PDF)

Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates

Antimicrobial agents and chemotherapy, 2018-04, Vol.62 (4)

2018

Volltextzugriff (PDF)

In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species

Antimicrobial Agents and Chemotherapy, 2012-03, Vol.56 (3), p.1613-1615

2012

Volltextzugriff (PDF)

Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial

The Lancet (British edition), 2005-11, Vol.366 (9498), p.1695-1703

2005

Volltextzugriff (PDF)

Update on the Taxonomy and Clinical Aspects of the Genus Fusobacterium

Clinical infectious diseases, 2002-09, Vol.35 (Supplement-1), p.S22-S27

CITRON, Diane M

2002

Volltextzugriff (PDF)

Ridinilazole: a novel therapy for Clostridium difficile infection

International journal of antimicrobial agents, 2016-08, Vol.48 (2), p.137-143

2016

Volltextzugriff (PDF)

Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains

Diagnostic microbiology and infectious disease, 2014-08, Vol.79 (4), p.438-440

2014

Volltextzugriff (PDF)

1 – 25 von 213

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(203)
Mit Volltextzugriff
(196)

Publikationsform

Artikel
(212)
Tagungsberichte
(1)

Sprache

Englisch
(213)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Science & Technology
(171)
Life Sciences & Biomedicine
(170)
Microbiology
(154)
Humans
(139)
Biological And Medical Sciences
(108)
Medical Sciences
(98)
Microbial Sensitivity Tests
(86)
Anti-Bacterial Agents - Pharmacology
(78)
Pharmacology & Pharmacy
(72)
Pharmacology. Drug Treatments
(71)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(70)
Infectious Diseases
(60)
Bacteria, Anaerobic - Drug Effects
(58)
Susceptibility
(53)
Antibacterial Agents
(41)
Anti-Bacterial Agents
(36)
Bacteria, Anaerobic - Isolation & Purification
(34)
Bacteria, Anaerobic
(33)
Bacteriology
(33)
Animals
(31)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O’Toole 1935) Prévot 1938

Lactobacillus Species: Taxonomic Complexity and Controversial Susceptibilities

Bacteriology of Moderate-to-Severe Diabetic Foot Infections and In Vitro Activity of Antimicrobial Agents

Description of two novel members of the family Erysipelotrichaceae: Ileibacterium valens gen. nov., sp. nov. and Dubosiella newyorkensis, gen. nov., sp. nov., from the murine intestine, and emendation to the description of Faecalibacterium rodentium

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin

Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates

Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II

Antimicrobial Activities of Fidaxomicin

In Vitro Activity of Tedizolid Compared to Linezolid and Five Other Antimicrobial Agents against 332 Anaerobic Isolates, Including Bacteroides fragilis Group, Prevotella , Porphyromonas , and Veillonella Species

Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes

Comparative susceptibility of Gemella morbillorum to 13 antimicrobial agents

Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities

In Vitro Activity of Biapenem plus RPX7009, a Carbapenem Combined with a Serine β-Lactamase Inhibitor, against Anaerobic Bacteria

Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence

Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

In vitro activity of eravacycline and comparator antimicrobials against 143 recent strains of Bacteroides and Parabacteroides species

Clostridium difficile Infection Among US Emergency Department Patients With Diarrhea and No Vomiting

Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates

In Vitro Activities of CB-183,315, Vancomycin, and Metronidazole against 556 Strains of Clostridium difficile, 445 Other Intestinal Anaerobes, and 56 Enterobacteriaceae Species

Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial

Update on the Taxonomy and Clinical Aspects of the Genus Fusobacterium

Ridinilazole: a novel therapy for Clostridium difficile infection

Comparative in vitro activities of dalbavancin and seven comparator agents against 41 Staphylococcus species cultured from osteomyelitis infections and 18 VISA and hVISA strains

Suchergebnisse filtern